Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil Regulator Rejects Sputnik V Vaccine Citing Serious Quality & Safety Concerns

Russian Backers Deny Risks & Say Move Is ‘Political’

Executive Summary

Sputnik V is the latest COVID-19 vaccine to be targeted over safety concerns, but Brazil’s Anvisa has also raised questions over quality and manufacturing standards.

You may also be interested in...



Coronavirus Notebook: G7 Agree On ‘Clinical Trial Charter’, Regulators Focus On Real World Data

The European Medicines Agency has issued advice on managing thrombosis with thrombocytopenia syndrome (TTS) in people vaccinated with adenovirus vaccines, and Brazil has OKd the import of Sputnik V and Covaxin, albeit with numerous strings attached.

Coronavirus Notebook: UK Seven-Vaccine Booster Trial Begins, Australia Plans mRNA Production Capacity

The company manufacturing Russia's Sputnik V vaccine in Brazil has produced the first batch, but has withdrawn a request to run clinical trials there. France is preparing to immunize the over-18s, and Australia has begun evaluating Vir/GSK’s sotrovimab for use in COVID-19 patients.

Dr Reddy’s Pilots Sputnik V Soft Launch In India, Explores CAR-T Space

Dr Reddy’s initiates pilot roll-out of imported Russian vaccine Sputnik V, currently priced at about $13.50 per dose in India, and indicates that it hopes to bring the single-dose version Sputnik Light to the country. The Indian company also strikes a deal with a Chinese firm for a CAR-T cell therapy, an area where it hopes to “pick up skills”.

Related Content

Topics

UsernamePublicRestriction

Register

PS144233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel